Search Results - "Ichiro, Iwanaga"

Technical difficulty according to location, and risk factors for perforation, in endoscopic submucosal dissection of colorectal tumors by Mizushima, Takeshi, Kato, Mototsugu, Iwanaga, Ichiro, Sato, Fumiyuki, Kubo, Kimitoshi, Ehira, Nobuyuki, Uebayashi, Minoru, Ono, Shouko, Nakagawa, Manabu, Mabe, Katsuhiro, Shimizu, Yuichi, Sakamoto, Naoya

“…Background Colorectal endoscopic submucosal dissection (ESD) is a widely accepted treatment for colorectal tumors, but is technically more difficult and has a…”
Get full text

Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer by Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Harada, Kazuaki, Nakano, Shintaro, Saito, Rika, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

“…Purpose Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been…”
Get full text

Open‐label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron by Komatsu, Yoshito, Okita, Kenji, Yuki, Satoshi, Furuhata, Tomohisa, Fukushima, Hiraku, Masuko, Hiroyuki, Kawamoto, Yasuyuki, Isobe, Hiroshi, Miyagishima, Takuto, Sasaki, Kazuaki, Nakamura, Michio, Ohsaki, Yoshinobu, Nakajima, Junta, Tateyama, Miki, Eto, Kazunori, Minami, Shinya, Yokoyama, Ryoji, Iwanaga, Ichiro, Shibuya, Hitoshi, Kudo, Mineo, Oba, Koji, Takahashi, Yasuo

“…The purpose of this study is to compare the efficacy of a single administration of dexamethasone (DEX) on day 1 against DEX administration on days 1–3 in…”
Get full text

Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer by Kawamoto, Yasuyuki, Komatsu, Yoshito, Yuki, Satoshi, Sawada, Kentaro, Muranaka, Tetsuhito, Harada, Kazuaki, Nakatsumi, Hiroshi, Fukushima, Hiraku, Ishiguro, Atsushi, Dazai, Masayoshi, Hatanaka, Kazuteru, Nakamura, Michio, Iwanaga, Ichiro, Uebayashi, Minoru, Sogabe, Susumu, Kobayashi, Yoshimitsu, Miyagishima, Takuto, Ono, Kota, Sakamoto, Naoya, Sakata, Yuh

“…In Japan, S-1 plus cisplatin (SP) regimen has become a standard therapy for patients with advanced gastric cancer. Moreover, the S-1 plus oxaliplatin regimen…”
Get full text

Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study by Sogabe, Susumu, Komatsu, Yoshito, Yuki, Satoshi, Kusumi, Takaya, Hatanaka, Kazuteru, Nakamura, Michio, Kato, Takashi, Miyagishima, Takuto, Hosokawa, Ayumu, Iwanaga, Ichiro, Sakata, Yuh, Asaka, Masahiro

“…After approval of bevacizumab in Japan, post-marketing surveillance studies reported on safety. However, few reports have shown the efficacy of bevacizumab as…”
Get full text

O15-2 HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy by Yokoyama, Tatsuya, Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Komatsu, Yoshito

Get full text

Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201) by Kawamoto, Yasuyuki, Yuki, Satoshi, Meguro, Takashi, Hatanaka, Kazuteru, Uebayashi, Minoru, Nakamura, Michio, Okuda, Hiroyuki, Iwanaga, Ichiro, Kato, Takashi, Nakano, Shintaro, Sato, Atsushi, Harada, Kazuaki, Oba, Koji, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

“…The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard…”
Get full text

HGCSG1902: Multicenter, prospective, observational study for patients with dysgeusia caused by chemotherapy for gastrointestinal cancer by Ito, Ken, Yuki, Satoshi, Nakatsumi, Hiroshi, Ando, Takayuki, Sawada, Kentaro, Yagisawa, Masataka, Ishiguro, Atsushi, Dazai, Masayoshi, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sato, Atsushi, Matsumoto, Ryusuke, Shindo, Yoshiaki, Tateyama, Miki, Muranaka, Tetsuhito, Katagiri, Masaki, Yokota, Isao, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

“…Abstract only 649 Background: Dysgeusia is the one of important adverse events in patients treated with chemotherapy because it could reduce daily oral intake…”
Get full text

Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial by Denda, Tadamichi, Takashima, Atsuo, Gamoh, Makio, Iwanaga, Ichiro, Komatsu, Yoshito, Takahashi, Masanobu, Nakamura, Masato, Ohori, Hisatsugu, Sakashita, Akiko, Tsuda, Masahiro, Kobayashi, Yoshimitsu, Baba, Hideo, Kotake, Masanori, Ishioka, Chikashi, Yamada, Yasuhide, Sato, Atsushi, Yuki, Satoshi, Morita, Satoshi, Takahashi, Shin, Yamaguchi, Tatsuro, Shimada, Ken

“…The TRICOLORE trial previously demonstrated that S-1 and irinotecan plus bevacizumab was non-inferior, based on progression-free survival (PFS), to…”
Get full text

Rescue technique using a diathermic dilator for an unremovable stent in malignant perihilar biliary obstruction by Sugiura, Ryo, Kawakami, Hiroshi, Ehira, Nobuyuki, Iwanaga, Ichiro, Uebayashi, Minoru, Kuwatani, Masaki, Sakamoto, Naoya

Get more information

Update result of HGCSG 1403: Phase I trial of oxaliplatin/irinotecan/S-1 (OX-IRIS) as first-line chemotherapy for unresectable pancreatic cancer by Nakano, Shintaro, Kawamoto, Yasuyuki, Yuki, Satoshi, Yagisawa, Masataka, Sawada, Kentaro, Muranaka, Tetsuhito, Nakatsumi, Hiroshi, Saiki, Takuro, Ishiguro, Atsushi, Harada, Kazuaki, Kobayashi, Yoshimitsu, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 359 Background: FOLFIRINOX has become one of the standard treatment for unresectable pancreatic cancer with distant metastasis. OX-IRIS is the…”
Get full text

Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP by Kobayashi, Yoshimitsu, Komatsu, Yoshito, Yuki, Satoshi, Fukushima, Hiraku, Sasaki, Takahide, Iwanaga, Ichiro, Uebayashi, Minoru, Okuda, Hiroyuki, Kusumi, Takaya, Miyagishima, Takuto, Sogabe, Susumu, Tateyama, Miki, Hatanaka, Kazuteru, Tsuji, Yasushi, Nakamura, Michio, Konno, Jun, Yamamoto, Fumiyasu, Onodera, Manabu, Iwai, Kazuhiro, Sakata, Yuh, Abe, Riichiro, Oba, Koji, Sakamoto, Naoya

“…We planned a randomized, open-label trial to evaluate differences between pre-emptive and reactive skin treatment for panitumumab (Pmab)-associated skin…”
Get full text

HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer by Kawamoto, Yasuyuki, Yuki, Satoshi, Hayashi, Hideyuki, Nakano, Shintaro, Sawada, Kentaro, Muranaka, Tetsuhito, Nakatsumi, Hiroshi, Saiki, Takuro, Ishiguro, Atsushi, Harada, Kazuaki, Kobayashi, Yoshimitsu, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

Get full text

O3-11-3HGCSG 1403: phase I trial of oxaliplatin /irinotecan /S-1 (OX-IRIS) for unresectable pancreatic cancer by Kawamoto, Yasuyuki, Yuki, Satoshi, Hayashi, Hideyuki, Nakano, Shintaro, Sawada, Kentaro, Muranaka, Tetsuhito, Nakatsumi, Hiroshi, Saiki, Takuro, Ishiguro, Atsushi, Harada, Kazuaki, Kobayashi, Yoshimitsu, Iwanaga, Ichiro, Hatanaka, Kazuteru, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

Get full text

Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab and failed: HGCSG 1201/OGSG1205 by Kawamoto, Yasuyuki, Meguro, Takashi, Yuki, Satoshi, Nakatsumi, Hiroshi, Sasaki, Takahide, Hatanaka, Kazuteru, Uebayashi, Minoru, Iwanaga, Ichiro, Abe, Nobuhiko, Nakamura, Michio, Okuda, Hiroyuki, Eto, Kazunori, Oba, Ayane, Abe, Masakazu, Oba, Koji, Satoh, Taroh, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito

“…Abstract only 151 Background: Some phase II and III studies of second-line chemotherapy for metastatic or advanced gastric cancer have been reported in recent…”
Get full text

North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer (NORTH/HGCSG1003) by Shichinohe, Toshiaki, Yuki, Satoshi, Takahashi, Norihiko, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Kusumi, Takaya, Ishiguro, Atsushi, Sogabe, Susumu, Iwanaga, Ichiro, Hatanaka, Kazuteru, Oomori, Kazuyoshi, Nakamura, Michio, Senmaru, Naoto, Iwai, Kazuhiro, Koike, Masahiko, Sakamoto, Naoya, Taketomi, Akinobu, Hirano, Satoshi, Ito, Yoichi M, Komatsu, Yoshito

“…Abstract only 807 Background: FOLFOX and XELOX are standard adjuvant chemotherapy for resected stage III colon cancer. MOSAIC and XELOXA trials were performed…”
Get full text

A multicenter prospective study on the efficacy and safety of denosumab in gastrointestinal cancer patients receiving short-term periodic steroid premedication for prevention of chemotherapy-induced nausea and vomiting: ESPRESSO-02/HGCSG1602 by Nakamura, Michio, Yagisawa, Masataka, Sawada, Kentaro, Muranaka, Tetsuhito, Nakatsumi, Hiroshi, Kawamoto, Yasuyuki, Yuki, Satoshi, Dazai, Masayoshi, Ishiguro, Atsushi, Kobayashi, Yoshimitsu, Sogabe, Susumu, Miyagishima, Takuto, Iwanaga, Ichiro, Tateyama, Miki, Hatanaka, Kazuteru, Ono, Kota, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only TPS809 Background: We previously reported that short-term periodic premedication of glucocorticoids (GCs) used with chemotherapy for…”
Get full text

Updated analysis of phase II trial of irinotecan/s-1/cetuximab (IRIS/Cet) as second-line treatment in patients with KRAS exon2 wild type metastatic colorectal cancer (mCRC): HGCSG0902—Comparison of administration interval in cetuximab treatment by Kondo, Tomohiro, Yuki, Satoshi, Kawamoto, Yasuyuki, Tsuji, Yasushi, Hosokawa, Ayumu, Nakamura, Michio, Muto, Osamu, Kato, Takashi, Iwanaga, Ichiro, Sato, Atsushi, Eto, Kazunori, Furukawa, Kouichi, Hayashi, Hideyuki, Tateyama, Miki, Takahashi, Yasuo, Sogabe, Susumu, Honda, Takuya, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 771 Background: HGCSG0902 is the multicenter phase II study to investigate the safety and efficacy of irinotecan, S-1 (IRIS) plus cetuximab as…”
Get full text

Observational cohort study of 1st line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by the GERCOR index by Muto, Osamu, Yuki, Satoshi, Muranaka, Tetsuhito, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Sato, Atsushi, Iwanaga, Ichiro, Uebayashi, Minoru, Tateyama, Miki, Hatanaka, Kazuteru, Eto, Kazunori, Okuda, Hiroyuki, Sogabe, Susumu, Abe, Masakazu, Kato, Kanji, Kato, Sosuke, Miyashita, Kencho, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 743 Background: The GERCOR index based on performance status and serum LDH was reported to be useful to predict survival for patients with…”
Get full text

Observational cohort study of first-line bevacizumab with oxaliplatin or irinotecan and fluoropyrimidines in metastatic colorectal cancer: HGCSG0802—Analysis of early tumor shrinkage (ETS) by Yuki, Satoshi, Nakatsumi, Hiroshi, Sawada, Kentaro, Kato, Takashi, Meguro, Takashi, Nakamura, Michio, Iwanaga, Ichiro, Ehira, Nobuyuki, Sonoda, Norikazu, Kudo, Mineo, Kato, Kanji, Sogabe, Susumu, Amano, Toraji, Ono, Kota, Sakamoto, Keita, Miyamoto, Noriyuki, Kudo, Kohsuke, Sakamoto, Naoya, Sakata, Yuh, Komatsu, Yoshito

“…Abstract only 753 Background: It was reported that early tumor shrinkage (ETS) was associated with better overall survival (OS) in patients (pts) with…”
Get full text